Previous Article | Next Article 
Infection and Immunity, August 1999, p. 3793-3799, Vol. 67, No. 8
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Analysis of the Immunological Responses to
Transferrin and Lactoferrin Receptor Proteins from
Moraxella catarrhalis
Rong-hua
Yu,1
Robert A.
Bonnah,1
Samuel
Ainsworth,2 and
Anthony B.
Schryvers1,*
Department of Microbiology and Infectious
Diseases, University of Calgary, Calgary, Alberta,
Canada,1 and Veterans Administration
Hospital, Alexandria, Louisiana2
Received 15 October 1998/Returned for modification 10 February
1999/Accepted 5 May 1999
 |
ABSTRACT |
Moraxella catarrhalis expresses surface receptor
proteins that specifically bind host transferrin (Tf) and lactoferrin
(Lf) in the first step of the iron acquisition pathway. Acute- and convalescent-phase antisera from a series of patients with M. catarrhalis pulmonary infections were tested against Tf and Lf receptor proteins purified from the corresponding isolates. After the
purified proteins had been separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and Western blotting, we
observed strong reactivity against Tf-binding protein B (TbpB; also
called OMP1) and Lf-binding protein B (LbpB) but little or no
reactivity against Tf-binding protein A (TbpA) or Lf-binding protein A
(LbpA), using the convalescent-phase antisera. Considerable antigenic
heterogeneity was observed when TbpBs and LbpBs isolated from different
strains were tested with the convalescent-phase antisera. Comparison to
the reactivity against electroblotted total cellular proteins revealed
that the immune response against LbpB and TbpB constitutes a
significant portion of the total detectable immune response to M. catarrhalis proteins. Preparations of affinity-isolated TbpA and
LbpA reacted with convalescent-phase antisera in a solid-phase binding
assay, but blocking with soluble TbpB, soluble LbpB, or extracts from an LbpA
mutant demonstrated that this reactivity was
attributed to contaminants in the TbpA and LbpA preparations. These
studies demonstrate the immunogenicity of M. catarrhalis
TbpB and LbpB in humans and support their potential as vaccine candidates.
 |
INTRODUCTION |
Moraxella catarrhalis is
a common inhabitant of the human upper respiratory tract and is
implicated as an important cause of upper respiratory infections in
children and of lower respiratory tract infections in the elderly
(33). M. catarrhalis has been shown to be
responsible for approximately 15% of the episodes of otitis media in
children on the basis of culture, and PCR analysis suggests that the
frequency of colonization may be even higher (33). Several
lines of evidence have confirmed this organism is a cause of infection
in chronic obstructive pulmonary disease patients, and it has been
reported to be responsible for up to 30% of exacerbations of disease
in these patients (33). The recognition of M. catarrhalis as a significant human pathogen and the increasing
prevalence of antibiotic resistance has prompted interest in
development of immunotherapeutic approaches to combat the threat of
disease caused by this organism.
A number of reports have explored the human immune response to M. catarrhalis infections as a logical first step in identifying potential vaccination targets (19, 25, 31, 43). This
approach has led to the identification of a number of candidate
antigens, including OMPB1 (12, 31, 43), CopB (1),
UspA (2, 13), and CD (44). Since there are
differences in the source of sera and the methodologies used in the
various studies, it is difficult to make comparisons of the
antigenicities of these candidate antigens in human infections.
Nevertheless, the use of active or passive immunization in animal
models has provided evidence for protective capacity of antibodies
directed against these antigens (1, 2, 13, 44).
Several members of the family Neisseriaceae, including
M. catarrhalis, have been shown to produce exquisitely host
specific receptors to allow iron acquisition from transferrin (Tf) and lactoferrin (Lf) during the infectious process (24). The
apparent inability of M. catarrhalis to utilize other
potential iron sources such as heme-hemopexin, hemoglobin, and
hemoglobin-haptoglobin (3) suggests an essential in vivo
role of these surface-exposed receptor proteins, making them putative
vaccine targets. The genes encoding these receptors, designated
Tf-binding proteins A and B (TbpA and -B) and Lf-binding proteins A and
B (LbpA and -B), have been recently identified (18, 34). The
comigration of transferrin binding activity with reactivity against
convalescent-phase sera (12) and inhibition of reactivity
against convalescent-phase sera by soluble receptor protein
(31) has been used to implicate TbpB as immunogenic protein
during infections. Until relatively recently, the identity of the Lf
receptor proteins in M. catarrhalis was uncertain
(20), and there is no information on the immunogenicity of
these proteins in humans. In this study, we assessed the abilities of
both the Tf and Lf receptors to elicit an immune response during a
natural pulmonary M. catarrhalis infection in humans and
confirmed their identities by several different methods.
 |
MATERIALS AND METHODS |
Bacterial strains and growth conditions.
Seventeen clinical
isolates from patients with pulmonary infections that were attributed
to M. catarrhalis based on microbiological analysis of
clinical samples (sputum, broncheoalveolar lavage fluid, and
transtracheal aspirate) were collected in conjunction with the acute-
and convalescent-phase sera used for this study. These isolates,
designated n130 to n144, were collected by S. Ainsworth, Veteran
Affairs Medical Center, Alexandria, La., and were from patients drawn
from a region encompassing northwestern Louisiana and Western Texas. In
an attempt to offset any geographical bias or features specifically
associated with isolates causing pulmonary diseases, we included a
limited selection of additional isolates: (i) three sputum isolates
(n056, n057, and n105) obtained from C. Anand, Foothills Hospital,
Calgary, Alberta, Canada; (ii) one pulmonary isolate (Q8) from M. Bergeron, University of Laval, Montreal, Quebec, Canada; (iii) one
otitis media isolate (4223) obtained from T. Murphy, State University
of New York, Buffalo; and (iv) three isolates (25240, 43627, and 43617)
obtained from the American Type Culture Collection.
Strains stored in 30% glycerol suspensions at
70°C were used to
inoculate chocolate agar plates and grown overnight at 37°C in an
atmosphere containing 5% CO2. The cells were used to
inoculate brain heart infusion broth cultures; after reaching mid-log
to late log phase of growth, the cells were subcultured (to a starting A600 of 0.05) into broth containing 100 µM
EDDA for iron limitation and incubated until late log-stationary phase
of growth.
Isolation of receptor proteins.
To screen for reactivity
against the native Tf and Lf receptor proteins (Fig. 1 and 2), the
proteins were isolated directly from intact M. catarrhalis
cells by modification of previously published procedures for isolation
of receptor proteins from crude total membrane preparations
(10). Cells collected after growth in iron-deficient media
were resuspended in 50 mM Tris-HCl (pH 8)-1 M NaCl (1 ml of buffer per
1 to 4 ml of culture), and the receptor proteins were solubilized by
the addition of EDTA (to 10 mM) and Sarkosyl (to 0.3%) and incubation
for 1 h at room temperature. After centrifugation (10 min, 13,000 rpm) to remove insoluble debris, the supernatant was applied to an
iron-loaded human Tf (hTf)-Sepharose or hLf-Sepharose resin and washed
three times with solubilization buffer (containing 0.15% Sarkosyl) and
then with 50 mM Tris-HCl, (pH 8) buffer prior to elution with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer.
Native Tf receptor complex (TbpA and TbpB) used in solid-phase binding
assays (Fig. 5) was isolated from crude total membrane preparations by
previously published procedures (10). Selective isolation of
TbpA was achieved by exposure of the solubilized membrane proteins to
apo-hTf-Sepharose, since TbpB does not bind to apo-Tf and thus remained
in the eluant (45). The eluant was analyzed for the presence
of TbpA and, if necessary, was exposed to additional apo-hTf-resin to
remove all remaining TbpA. The TbpA-depleted eluant was applied to a
column containing the iron-loaded form of hTf-Sepharose to isolate
TbpB. Native Lf receptor (LbpA and LbpB) or LbpA for the solid-phase
binding assays was isolated essentially as described previously
(10) except that membranes prepared from an isogenic
LbpB
mutant (9) was used for LbpA isolation.
Bound receptor proteins were eluted from the various columns by the
addition of 100 ml of buffer containing >2 M guanidine hydrochloride,
dialyzed against three changes of 50 mM Tris buffer (pH 8.0), and then
dialyzed against ammonium bicarbonate before lyophilization and storage at
20°C.
For production of maltose-binding protein (Mbp) fusion proteins
(Mbp::Tbp and Mbp::Lbp) lacking a signal peptide,
specific primers (Table 1) were designed
to allow PCR amplification of the tbpA or tbpB
gene from strain 4223 or the lbpA or lbpB gene from strain N141. Primers were designed to allow in-frame ligation to
the malE gene of pMal-c2 (New England Biolabs, Mississauga, Ontario, Canada). Expression of the Mbp fusion proteins was induced by
the addition of isopropyl-
-D-thiogalactoside (IPTG) to
Escherichia coli DH5
cells containing the pMal-c2
derivative plasmid as described previously (8).
Collection and preparation of antisera.
Sera were collected
from patients with pulmonary infections attributed to M. catarrhalis based on microbiological analysis of clinical samples
(sputum, broncheoalveolar lavage fluid, or transtracheal aspirate).
Sera were collected at the time which the symptoms were first reported
(acute-phase sera) and after resolution of the infection after
treatment (convalescent-phase sera) and stored at
20°C.
For the production of antiserum in New Zealand White rabbits, 50 µg
of purified receptor protein emulsified in complete Freund's adjuvant
was used for the first intramuscular injection and boosted on days 14 and +29 with the same dose of protein emulsified in incomplete
Freund's adjuvant after the primary injection.
Western blot or solid-phase immunoblot analysis.
SDS-PAGE
samples were boiled in Laemmli sample buffer and separated by SDS-PAGE
using a 7% acrylamide gel with the Tris-HCl-glycine buffer system
(28). Proteins were transferred to Immobilon-P (Millipore,
Bedford, Mass.) and stained for protein (amido black) or probed with
specific antisera as described previously (10).
Samples of purified receptor proteins were either directly applied onto
Nitro ME-nitrocellulose (Micron Separations, Westboro, Mass.) membranes
or placed into a dot blot apparatus with vacuum apparatus attached. The
remaining binding sites on the blot were blocked by incubation for 30 min with Tris-buffered saline containing 0.5% blotting-grade nonfat
dry milk blocker (Bio-Rad Laboratories). After removal of blocking
buffer, the membranes were exposed to the indicated dilution of the
patient acute- or convalescent-phase sera in blocking solution and
incubated for 1 h. Where indicated, purified, recombinant fusion
proteins (Mbp::TbpB or Mbp::LbpB) were added to the
diluted antisera at a final concentration of 100 µg/ml and incubated
for 1 h prior to exposure to the membrane. Similarly, 100 µl of
crude cellular extracts of the LbpA
mutant obtained by
French press lysis (10 mg of cellular protein/ml of buffer) was added
per 5 ml of diluted antisera and incubated for 1 h prior to
exposure to the membrane. After incubation, the diluted antisera was
removed, the membrane washed and then exposed to a 1/2,000 dilution of
horseradish peroxidase-conjugated goat anti-human immunoglobulin G
(IgG)-IgM-IgA and incubated for 1 h. The second antibody solution
was removed; the membrane washed and then developed with horseradish
peroxidase color development reagent (Bio-Rad).
 |
RESULTS |
Analysis of the immune response to native Tf and Lf receptor
proteins.
A total of 17 paired sera from patients with pulmonary
infections attributable to M. catarrhalis were collected,
and isolates from 15 of the 17 paired sera were available for analysis.
To specifically evaluate the immune response against Tf and Lf receptor proteins from these isolates, we isolated the receptor proteins by
affinity techniques. To facilitate analysis from a large number of
strains, we adapted our affinity isolation techniques to isolate receptor proteins directly from intact cells (see Materials and Methods). Several additional strains, used for more extensive analysis
of the receptor proteins (11, 18, 34), were also included
for comparison. Figure 1 illustrates the
results obtained with one of the clinical isolates from this series,
N141, and with an otitis media isolate that we have worked with
previously, 4223 (45). The modified procedure enabled us to
obtain relatively pure preparations of Tf receptor proteins with an
hTf-Sepharose resin (Fig. 1A, lanes 1 and 2, TbpA and TbpB) and
relatively pure preparations of Lf receptor proteins with an
hLf-Sepharose resin (Fig. 1B, lanes 1 and 2, LbpA and LbpB). We used
SDS-polyacrylamide gels with a lower-percentage acrylamide (7%) to
optimally resolve LbpB from LbpA, since these two proteins comigrate on
conventional (10%) gels (11).

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 1.
Assessment of the ability of Tf and Lf receptor proteins
to elicit an immune response. Using hTf-Sepharose (A) or hLf-Sepharose
(B) as the affinity matrix, we isolated receptor proteins from
iron-starved cells of M. catarrhalis 4223 and N141. The
proteins were eluted by boiling in Laemmli sample buffer and subjected
to SDS-PAGE (7% gel), and Western blots were prepared. The blots were
either stained for protein (lanes 1, 2) or blocked and then probed with
rabbit polyclonal antiserum (lanes 3 and 4; 1/5,000 dilution), human
convalescent-phase serum (lanes 5 and 6; 1/200 dilution), or human
acute-phase serum (lanes 7 and 8; 1/200 dilution). The human sera were
obtained from the patient with a pulmonary infection attributed to
M. catarrhalis N141.
|
|
The ability of the Tf and Lf receptor proteins to elicit an immune
response during the course of a natural infection in humans was
assessed by Western blot analysis. Electroblotted receptor proteins
were probed with either acute-phase or convalescent-phase sera from
patients with a pulmonary infection attributed to M. catarrhalis. Figure 1 illustrates the results obtained with a representative set of paired antisera from a patient infected with
strain N141. Significant reactivity against the lower-molecular-weight component of either the Tf receptor (Fig. 1A, lanes 5 and 6, TbpB) or
Lf receptor (Fig. 1B, lanes 5 and 6, LbpB) from either the infecting
strain N141 or strain 4223 was observed with the convalescent-phase antiserum. In contrast, little reactivity to either TbpA or LbpA was
observed with either strain. When the acute-phase antiserum was tested,
little reactivity was noted with the Tf (Fig. 1A, lanes 7 and 8) and Lf
(Fig. 1B, lanes 7 and 8) receptor proteins.
In a preliminary attempt to address the potential cause of the lack of
reactivity of TbpA and LbpA with the convalescent-phase antiserum, we
decided to test the immunogenicity of the purified proteins in rabbits.
Polyclonal antisera were prepared by immunizations with
affinity-purified receptor preparations from strain 4223 emulsified in
Freund's adjuvant and tested against the electroblotted receptor
preparations. In contrast to the convalescent-phase antiserum, the
rabbit polyclonal serum reacted strongly with electroblotted TbpA from
either the homologous strain (Fig. 1A, lane 3) or a heterologous strain
(lane 4). Similarly, the rabbit antiserum prepared against purified Lf
receptor reacted with LbpA from the homologous strain (lane 3) or the
heterologous strain (lane 4). Thus, the lack of reactivity of TbpA and
LbpA with the convalescent-phase antiserum does not appear to be due to
some intrinsic property of these proteins.
The results obtained with the antisera from the patient infected with
strain N141 are fairly representative. There was substantial reactivity
against TbpB and LbpB from the infecting strain in all of the
convalescent-phase antisera and little or no reactivity against these
proteins in 14 of 17 of the acute-phase sera (data not shown). However,
the acute-phase antisera from three of the patients had detectable
reactivity against LbpB and/or TbpB, albeit less than that observed in
the convalescent-phase antisera. This is perhaps not surprising, as
most of the infections were acute exacerbations in elderly patients
with chronic bronchitis, and we could not exclude the possibility of
prior subclinical infection in these patients. We were unable to
demonstrate reactivity of any of the convalescent antisera against TbpA
or LbpA.
Analysis of TbpB and LbpB heterogeneity.
The
convalescent-phase antisera were tested against receptor proteins
isolated from a collection of 23 strains, including all of the clinical
isolates from the pulmonary infections, to assess the immunological
heterogeneity of the TbpB proteins. The results demonstrated that there
was considerable antigenic heterogeneity among TbpBs from different
strains, and although the individual antisera appeared to provide a
preliminary basis for grouping of the strains, the analysis did not
result in any consistent groupings (data not shown). Figure
2 illustrates representative data for
convalescent-phase antisera from three patients against TbpBs from
three of the strains. The convalescent-phase antiserum from a patient
infected with strain N137 demonstrated strong reactivity against TbpBs
from all three strains (4223, Q8, and N141), whereas the antisera from
the patients infected with strain N141 and strain N132 reacted
predominantly with TbpBs from two of the strains (4223 and N141 or Q8
and N141, respectively). These results suggest that several variable
immunodominant epitopes are present on TbpBs from different M. catarrhalis strains. Although immunization of rabbits with
purified Tf receptor proteins provided antiserum that could cross-react
with receptor proteins from all strains (1/5,000 dilution [data not
shown]), the distinctive pattern of reactivity due to the
immunodominant epitopes was evident at higher dilutions (1:20,000).

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 2.
Analysis of host immune response to Tf and Lf receptor
proteins from homologous and heterologous M. catarrhalis
strains. Using hTf-Sepharose or hLf-Sepharose as the affinity matrix,
we isolated receptor proteins from iron-starved cells of M. catarrhalis 4223, Q8, and N141. The proteins were eluted from the
matrix by boiling in Laemmli sample buffer and subjected to SDS-PAGE
(7% gel), and replicate Western blots were prepared. The blots were
either stained for protein (A) or blocked and probed with
convalescent-phase antisera (1/200 dilution) obtained from patients
infected with M. catarrhalis N137 (B), N141 (C) or N132
(D).
|
|
The analysis of antigenic heterogeneity was also performed on the Lbp
proteins isolated from different strains. In most cases, the reactivity
to LbpB was more intense than the reactivity of the same sera to TbpB
from that strain, using equivalent serum dilutions (Fig. 2). As with
the TbpBs, there was evidence of antigenic heterogeneity between LbpB
proteins from different strains, although the differences were not as
apparent when similar dilutions of the antiserum were used (Fig. 2).
Recombinant Tbp and Lbp analysis.
Affinity isolation of the Tf
and Lf receptor proteins was performed for the serological analysis to
facilitate identification of antibodies directed specifically against
these proteins. The identification of the individual receptor proteins
(TbpA, TbpB, LbpA, and LbpB) was based on their relative mobility in
SDS-polyacrylamide gels as demonstrated in previous studies (10,
11, 41). However, the similar migration of LbpA and LbpB in
SDS-polyacrylamide gels and the appearance of multiple immunoreactive
bands, even in the affinity-isolated samples (Fig. 2), raised some
concern about the identification of the specific proteins. To
definitively confirm the identity of the immunoreactive bands with
convalescent-phase sera, we prepared recombinant receptor proteins with
the genes encoding the receptor proteins from M. catarrhalis
(18, 34).
The regions encoding each of the mature receptor proteins were PCR
amplified from chromosomal DNA and cloned in frame to the malE gene of the pMal-c2 vector. SDS-polyacrylamide gels of
cells containing the expressed Mbp fusions were either stained for
protein (Fig. 3, lanes 1 to 4) or
electroblotted and incubated with convalescent-phase antiserum (lanes 5 and 6) from the patient infected with strain N141. As occurred with the
native proteins, the convalescent-phase antiserum reacted with
recombinant TbpB (lane 6) and LbpB (lane 8) but not with recombinant
TbpA (lane 5) or LbpA (lane 7). Some of the samples exhibited multiple
immunoreactive bands (lane 8), which we attribute to breakdown products
and/or complexes of the recombinant receptor fusion proteins since they
are absent in the other samples. When tested after electroblotting,
only Mbp::TbpB and Mbp::LbpB retained ligand
binding activity (data not shown), supporting our prior designations
for these proteins based on their functional attributes (11,
45).

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 3.
Reactivity of convalescent-phase sera to recombinant Tf
and Lf receptors. The regions encoding the mature forms of the
individual Tf and Lf receptor proteins were PCR amplified and ligated
in frame with the malE gene of the pMal-c2 vector for
production of Mbp fusion proteins. Expression of the Mbp fusions was
induced by the addition of IPTG, and the cells were boiled in Laemmli
sample buffer prior to SDS-PAGE (7% gel). The electroblotted proteins
were either stained for protein (lanes 1 to 4) or probed with
convalescent-phase antiserum (1:500) from the patient with a pulmonary
infection attributed to M. catarrhalis N141. Lanes 1 and 5, Mbp::TbpA (strain 4223 tbpA gene); lanes 2 and 6, Mbp::TbpB (strain 4223 tbpB gene); lanes 3 and 7, Mbp::LbpA (strain N141 lbpA gene); lanes 4 and 8, Mbp::LbpB (strain N141 lbpB gene). Symbols are as
in Fig. 1 and 2.
|
|
Although our analysis confirmed that an immune response was generated
against TbpB and LbpB, we wanted to assess this response relative to
the response against other M. catarrhalis proteins. To this
end, we isolated total cellular proteins (Fig.
4, lane 1), Tf receptor proteins (lane
2), and Lf receptor proteins (lane 3) from M. catarrhalis
and tested them for reactivity against acute-phase (lanes 4 to 6) and
convalescent-phase (lanes 7 to 9) sera. The convalescent-phase
antiserum reacted with a number of different protein bands in the
sample representing total cellular proteins (lane 7). There was a
strong immunoreactive band that comigrated with the affinity-purified
LbpB (lane 9) and a weaker band of immunoreactivity that comigrated
with affinity-purified TbpB (lane 8). To demonstrate that the
reactivity was directed toward TbpB and LbpB, respectively, we
preincubated the convalescent-phase sera with amylose resin-affinity
purified Mbp::TbpB and Mbp::LbpB. Subsequently, the
convalescent-phase sera demonstrated little or no reactivity with
either the purified native TbpB (lane 11) or LbpB (lane 12). In
addition, the reactivity of the sera with the total cellular proteins
decreased dramatically at the regions that comigrated with the TbpB and
LbpB (lane 10), confirming the identity of these immunoreactive regions
as TbpB and LbpB.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of immune response to M. catarrhalis
total cellular proteins. The Tf receptor proteins from M. catarrhalis 4223 (lanes 2, 5, 8, and 11) or the Lf receptors from
strain N141 (lanes 3, 6, 9, and 12) were isolated by using either
hTf-Sepharose or hLf-Sepharose as the affinity matrix. The receptor
proteins or strain N141 whole cells (lanes 1, 4, 7, and 10) were boiled
in Laemmli sample buffer and subjected to SDS-PAGE (7% gel), and
replicate Western blots were prepared. The blots were either stained
for protein (lanes 1 to 3) or blocked and probed with either
acute-phase sera from the patient infected with M. catarrhalis N141 (lanes 4 to 6), the convalescent-phase sera alone
(lanes 7 to 9), or the convalescent-phase sera containing approximately
1 mg each of Mbp::TbpB and Mbp::LbpB purified by
amylose affinity chromatography.
|
|
Solid-phase immunological and functional analysis.
Since the A
constituents of the Tf and Lf receptors lose their ligand binding
capacity after SDS-PAGE and Western blotting, we were concerned that
our inability to detect anti-TbpA or anti-LbpA antibodies could be due
to conformationally dependent epitopes destroyed by the denaturing
conditions of SDS-PAGE. Therefore, we sought to provide the receptor
proteins with a more native conformation for detection of
convalescent-phase serum reactivity. The affinity isolation methods
provide pure preparations of receptor proteins, and although they
require relatively harsh conditions for elution of the bound
proteins, we have been able to restore ligand binding in the purified
receptor preparations, suggesting that native conformation is at least
partially restored. However, receptor isolated from wild-type strains
contain both the A and B components, and thus we needed to separate the
individual receptor proteins by biochemical or genetic means.
For the preparation of LbpA, we fortunately had a recently constructed
LbpB
isogenic mutant (9) in which the
wild-type lbpB gene had been replaced with an insertionally
inactivated copy. LbpA isolated from this strain with an hLf-Sepharose
affinity column retained substantial Lf binding activity in solid-phase
binding assays (data not shown). We also were able to readily purify
the recombinant fusion proteins containing mature LbpA and LbpB
(Mbp::LbpA and Mbp::LbpB, respectively), but only
the fusion containing LbpB retained significant Lf binding activity in
solid-phase binding assays (data not shown). These various LbpA and
LbpB preparations, along with native receptor complex (LbpA and LbpB)
isolated from the wild-type parent, were tested in a solid-phase
binding assay for reactivity against the convalescent-phase antiserum
(Fig. 5). In this assay, excess
Mbp::TbpB or Mbp::LbpB was premixed with the
convalescent-phase antiserum to bind antibody against these proteins.
The loss of reactivity of the antiserum against Mbp::LbpB,
Mbp::TbpB, and native TbpB (Fig. 5) demonstrated that this
preincubation was effective at eliminating the binding activity.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 5.
Solid-phase immunological analysis. Native Tf receptor
proteins were affinity isolated with apo- or holo-hTf-Sepharose from
M. catarrhalis 4223 (TbpA and TbpB, TbpA alone, or TbpB
alone). Native Lf receptor proteins were affinity isolated with
holo-hLf-Sepharose from strain N141 or from an N141 LbpB
isogenic mutant (9). The Mbp receptor protein fusions were
affinity isolated by using an amylose resin. Approximately 50 ng of
isolated protein was spotted onto the nitrocellulose matrix and
incubated with a 1:1,000 dilution of convalescent-phase sera from the
patient infected with M. catarrhalis N141 (sera alone;
columns 1 and 4), the same sera preincubated with approximately 1 mg of
either Mbp::TbpB (column 2) or Mbp::LbpB (column 3)
or with 100 µl of a crude extract from the N141 LbpA
isogenic mutant (9) (column 5).
|
|
The solid-phase binding assay demonstrated that there was substantial
reactivity of the convalescent-phase antiserum against purified
receptor complex (native LbpA and LbpB) and LbpA purified from the
isogenic mutant (native LbpA), even in the presence of excess competing
Mbp::LbpB (Fig. 5). There was relatively little reactivity
against Mbp::LbpA under these conditions, initially suggesting most of the reactive antibody was directed against conformationally dependent epitopes, since this latter LbpA preparation was deficient in Lf binding activity. To exclude the possibility that
the reactivity observed against the native LbpA preparations was due to
a contaminant (i.e., lipopolysaccharide) isolated from M. catarrhalis, the convalescent antiserum was preincubated with crude extracts obtained from an LbpA
isogenic mutant of
M. catarrhalis (14). As illustrated in Fig. 5,
preincubation with the LbpA
mutant essentially eliminated
reactivity against native receptor complex and LbpA, demonstrating that
there was no reactivity directed against LbpA and that any apparent
reactivity was due to some contaminant in the affinity-isolated LbpA preparation.
The preferential binding of TbpB to the iron-loaded form of hTf
(45) enabled us to use affinity methods to purify and
separate native TbpA and TbpB from M. catarrhalis. This
preparation of TbpA retained substantial hTf binding activity in
solid-phase binding assays, unlike electroblotted TbpA. As an alternate
source of the individual Tf receptor proteins, we used recombinant
fusion proteins containing the intact mature TbpA and TbpB proteins
fused to Mbp which were isolated and purified with an amylose affinity column. The convalescent-phase serum demonstrated significant levels of
reactivity with native receptor complex (TbpA and TbpB), native TbpB,
Mbp::TbpB, and to a lesser extent native TbpA (Fig. 5).
Although the method of production of native TbpA resulted in relatively
pure preparations based on SDS-PAGE analysis (45), we could
not exclude the possibility that trace amounts of TbpB were responsible
for the reactivity observed against the native TbpA preparation.
Therefore, the sera were preincubated with excess amounts of
Mbp::TbpB, or Mbp::LbpB, as a control. The
pretreatment with Mbp::TbpB resulted in a substantial
decrease in the reactivity against the native TbpA preparation,
indicating that contaminating TbpB must have been responsible for a
substantial amount of the observed reactivity. Although there was a
weak but detectable reactivity remaining against the native TbpA
preparation in the presence of excess competing Mbp::TbpB,
this was also detected in the native TbpB preparation, suggesting that
it may be due to reactivity against contaminants in these preparations.
Unfortunately, we do not have isogenic TbpA
or
TbpB
strains of M. catarrhalis that would have
allowed us to address this question.
 |
DISCUSSION |
Tf receptors in pathogenic gram-negative bacteria from the
families Pasteurellaceae and Neisseriaceae play a
critical role in acquisition of iron from Tf (7, 15, 23,
27), which appears to be an essential process for survival in
vivo (16). Lf receptors in members of the
Neisseriaceae are similarly required for acquisition of iron
from Lf (8, 9, 29, 35), but the importance of this function
in vivo has not been established. The role that these receptor proteins
play and their requisite surface accessibility suggest that they may
serve as ideal candidates for vaccines and has led to considerable
effort at evaluating their utility.
As TbpB is a largely exposed surface lipoprotein anchored by its fatty
acyl tails (24), it may be a reasonable target for immunotherapy. The bactericidal activity of antisera prepared against
receptor complex from Neisseria meningitidis in rabbits was
directed against TbpB (17), suggesting that it may be a more
useful target for vaccine development. Further, studies indicate that
recombinant TbpBs (produced in E. coli) from N. meningitidis (38), Haemophilus influenzae
(30), and M. catarrhalis (34) retain
their propensity to bind Tf and ability to generate strain-specific bactericidal and protective anti-TbpB antibodies. Thus, industrial production of TbpB suitable for vaccination purposes may be an achievable goal. The homologue of TbpB involved in Lf iron acquisition has only recently been identified and characterized (8, 11, 29,
35); thus, there is little information on its potential as a
vaccine antigen. Nevertheless, recent studies have shown that
recombinant LbpB from M. catarrhalis is capable of inducing bactericidal antibodies (11), suggesting that its potential as a vaccine antigen may parallel that of TbpB.
The ability to produce functional antibody in animals supports the
potential utility of TbpB and LbpB for human vaccines, but evidence
from the human host is ultimately required. Previous studies have
demonstrated that convalescent-phase sera from patients infected with
H. influenzae (26) or N. meningitidis
(6, 21) contains antibody directed against TbpBs. Similarly,
convalescent-phase antisera from a natural infection by M. catarrhalis reacted strongly with OMPB1 (43), which was
shown to comigrate with Tf binding activity (12), suggesting
that the antibody was directed against TbpB. However, comigration is
not necessarily a good basis for identification, as the experience with
initial identification of TbpB (42) and subsequent confusion
with a major 70-kDa protein (4) demonstrate. The use of
affinity-purified protein as target (Fig. 1 and 2) or as a blocking
agent (31) provides more convincing evidence for a human
anti-TbpB response. Furthermore, the use of recombinant TbpB protein as
a target for antibody (Fig. 3) or to competitively block reactivity in
the binding assays (Fig. 4 and 5) enables us to conclusively state that
there is a substantial human antibody response directed against
M. catarrhalis TbpB. Our results (Fig. 1 to 5) also enable
us to definitively conclude that there is a substantial antibody
response directed against LbpB after natural M. catarrhalis
infection. The recent identification of LbpB from N. meningitidis (8, 29, 35) should facilitate similar
studies with receptor from that species.
Although there are studies demonstrating an antibody response against
TbpB and LbpB in humans, there is no evidence for production of
functional human antibody against these proteins. However, recombinant
TbpBs from veterinary pathogens have been successfully used in active
immunization experiments in the native host (36, 40), which,
by inference, suggests that production of functional antibody in humans
is possible.
A considerable degree of genetic and antigenic heterogeneity has been
demonstrated for TbpBs from N. meningitidis (32), H. influenzae (30), and M. catarrhalis
(34), probably a consequence of their surface exposure and
immunogenicity. Antigenic variation clearly has important implications
regarding consideration of TbpB as a vaccine antigen; thus, it is
noteworthy that despite the considerable variation, two meningococcal
TbpBs were capable of producing functional antibody that cross-reacted
with a representative collection of meningococcal strains
(39). Analysis of the human antibody response to M. catarrhalis TbpBs also demonstrates the antigenic heterogeneity of
these proteins (Fig. 2). Analysis of the predicted amino acid sequences
of TbpBs and the bactericidal activity of guinea pig antisera suggests
that there may be two broad groups of TbpBs (34),
reminiscent of the situation with meningococcal TbpBs (37).
In this context, it is interesting that although some of the human
antisera readily discriminated between the representative strains from
these two groups (4223 and Q8; N141 and N137 antisera [Fig. 2]),
other antisera were capable of recognizing both TbpBs (N137 antiserum).
Since LbpBs have only recently been identified (8, 11, 29,
35), there is less information available on genetic and antigenic
heterogeneity among these proteins. Sequence comparisons among LbpBs
from M. catarrhalis revealed comparatively high levels of
identity (77% among LbpBs from three strains) (11).
Surprisingly, there is complete identity among the published sequences
of meningococcal LbpBs (8, 29, 35). To exclude the
possibility that this is a consequence of use of the same strains (even
though different strain names were reported), sequences from additional
strains will be required. The analysis of human antisera from patients with M. catarrhalis infections demonstrated the presence of
cross-reactive antibody against heterologous Lbps (Fig. 1 and 2), but
the functionality of this antibody is not known. Preliminary evidence
for cross-reactive bactericidal activity of antisera raised against
M. catarrhalis LbpBs in guinea pigs are encouraging
(11), but the results indicate that in spite of greater
sequence similarity, there still is sufficient antigenic heterogeneity
to necessitate inclusion of several representative LbpBs for
broad-spectrum coverage.
The critical roles that TbpA and LbpA play in iron acquisition from Tf
and Lf suggest that they might be preferred targets for immunotherapy.
However, several features have limited their consideration for vaccine
development. Unlike TbpB and LbpB, recombinant TbpA and LbpA have
failed to produce bactericidal antibodies (18, 34). TbpA
requires export and assembly in the outer membrane to attain a native
conformation capable of binding ligand (22), which may also
be necessary for induction of functional antibody (5, 6).
This requirement may ultimately limit consideration of intact
recombinant protein as a vaccine antigen.
Analysis of convalescent human antisera from patients with
meningococcal (6, 21) or M. catarrhalis (Fig. 1,
2, and 4) infections has failed to detect anti-TbpA or anti-LbpA
antibody against electroblotted proteins. Since this could also be
attributed to failure of electroblotted TbpA and LbpA to attain the
appropriate conformation necessary for binding antibody, attempts have
been made to use purified TbpA or LbpA in solid-phase binding assays (6) (Fig. 5). Indeed some antibody binding activity is
detected in preparations of purified TbpA or LbpA (6) (Fig.
5), albeit less than that observed for TbpB or LbpB. Substantial loss
of antibody binding by prior denaturation of the receptor protein (6) provides additional evidence for the antibody being
directed at conformational epitopes in TbpA.
One disadvantage of using purified receptor proteins isolated from the
original bacterium to evaluate reactivity against human antisera is
that it is difficult to totally exclude the contribution of
contaminants in the receptor preparation, in spite of the apparent purity by conventional analyses. Thus, addition of extracts from an
LbpA
isogenic mutant to dilutions of the human
convalescent-phase antiserum effectively eliminated reactivity against
purified LbpA (Fig. 5). This finding indicates that the reactivity was
due not to LbpA but to some contaminant in the preparation, even though there were no contaminants evident in SDS-PAGE analysis of the affinity-purified LbpA preparation (data not shown). Similarly, although there was no TbpB detected in the purified preparation of TbpA
(data not shown), addition of excess recombinant TbpB significantly
reduced the detected reactivity against the TbpA preparation (Fig. 5).
It is certainly possible that the remaining reactivity was directed
against TbpA, but since we did not have an available TbpA
isogenic mutant of M. catarrhalis, we could not exclude the
possibility that it was due to other contaminants in the TbpA preparation.
At present we have no conclusive evidence for antibody against TbpA or
LbpA from M. catarrhalis in convalescent-phase human sera.
In this context, it is interesting that cattle immunized with purified
(and functional) preparations of TbpA isolated from the cattle pathogen
Pasteurella haemolytica exhibited little or no anti-TbpA
antibody response, whereas a robust anti-TbpB response was detected in
animals immunized with recombinant TbpB, using the same adjuvant
(36). This finding suggests that TbpA may not be immunogenic
in the native host, which could possibly be a selected attribute of
this protein since, unlike TbpB, it is not subject to the same degree
of antigenic variation. Immunization experiments with TbpAs from other
veterinary pathogens (in their native hosts) would be useful to
establish whether this is a general property of TbpAs. In addition, it
may be warranted to reevaluate the evidence for antibody against TbpA
from N. meningitidis in convalescent-phase antisera
(6), as this also has implications on the immunogenicity of
TbpA in the native host and the utility of TbpA as a vaccine antigen.
More extensive studies on the immune response against this protein may
be essential if TbpA or its derivatives are to be considered for
vaccination purposes.
 |
ACKNOWLEDGMENTS |
This research was supported by grants MT10350 and UI-13041 from
the Medical Research Council of Canada.
We thank Sheena Loosmore and Robin Harkness from Pasteur-Merieux
Connaught for their advice and support.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Infectious Diseases, University of Calgary, 3330 Hospital Dr., N.W., Calgary, Alberta, T2N 4N1, Canada. Phone:
403-220-3703. Fax: 403-270-2772. E-mail:
schryver{at}acs.ucalgary.ca.
Editor:
J. R. McGhee
 |
REFERENCES |
| 1.
|
Aebi, C.,
L. D. Cope,
J. L. Latimer,
S. E. Thomas,
C. A. Slaughter,
G. H. McCracken, Jr., and E. J. Hansen.
1998.
Mapping of a protective epitope of the CopB outer membrane protein of Moraxella catarrhalis.
Infect. Immun.
66:540-548[Abstract/Free Full Text].
|
| 2.
|
Aebi, C.,
I. Maciver,
J. L. Latimer,
L. D. Cope,
M. K. Stevens,
S. E. Thomas,
G. H. McCracken, Jr., and E. J. Hansen.
1997.
A protective epitope of Moraxella catarrhalis is encoded by two different genes.
Infect. Immun.
65:4367-4377[Abstract].
|
| 3.
|
Aebi, C.,
B. Stone,
M. Beucher,
L. D. Cope,
I. Maciver,
S. E. Thomas,
G. H. McCracken, Jr.,
P. F. Sparling, and E. J. Hansen.
1996.
Expression of the CopB outer membrane protein by Moraxella catarrhalis is regulated by iron and affects iron acquisition from transferrin and lactoferrin.
Infect. Immun.
64:2024-2030[Abstract].
|
| 4.
|
Ala'Aldeen, D. A.,
H. A. Davies,
R. A. Wall, and S. P. Borriello.
1990.
The 70 kilodalton iron regulated protein of Neisseria meningitidis is not the human transferrin receptor.
FEMS Microbiol. Lett.
69:37-42.
|
| 5.
|
Ala'Aldeen, D. A. A., and S. P. Borriello.
1996.
The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains.
Vaccine
14:49-53[Medline].
|
| 6.
|
Ala'Aldeen, D. A. A.,
P. Stevenson,
E. Griffiths,
A. R. Gorringe,
L. I. Irons,
A. Robinson,
S. Hyde, and S. P. Borriello.
1994.
Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design.
Infect. Immun.
62:2984-2990[Abstract/Free Full Text].
|
| 7.
|
Anderson, J. A.,
P. F. Sparling, and C. N. Cornelissen.
1994.
Gonococcal transferrin-binding protein 2 facilitates but is not essential for transferrin utilization.
J. Bacteriol.
176:3162-3170[Abstract/Free Full Text].
|
| 8.
|
Bonnah, R. A., and A. B. Schryvers.
1998.
Preparation and characterization of Neisseria meningitidis mutants deficient in the production of the human lactoferrin binding proteins LbpA and LbpB.
J. Bacteriol.
180:3080-3090[Abstract/Free Full Text].
|
| 9.
|
Bonnah, R. A.,
H. Wong,
S. M. Loosmore, and A. B. Schryvers.
1999.
Characterization of Moraxella (Branhamella) catarrhalis lbpB, lbpA, and lactoferrin receptor orf3 isogenic mutants.
Infect. Immun.
67:1517-1520[Abstract/Free Full Text].
|
| 10.
|
Bonnah, R. A.,
R.-H. Yu, and A. B. Schryvers.
1995.
Biochemical analysis of lactoferrin receptors in the Neisseriaceae: identification of a second bacterial lactoferrin receptor protein.
Microb. Pathog.
19:285-297[Medline].
|
| 11.
|
Bonnah, R. A.,
R.-H. Yu,
H. Wong, and A. B. Schryvers.
1998.
Biochemical and immunological properties of lactoferrin binding proteins from Moraxella (Branhamella) catarrhalis.
Microb. Pathog.
24:89-100[Medline].
|
| 12.
|
Campagnari, A. A.,
T. F. Ducey, and C. A. Rebmann.
1996.
Outer membrane protein B1, and iron-repressible protein conserved in the outer membrane of Moraxella (Branhamella) catarrhalis, binds human transferrin.
Infect. Immun.
64:3920-3924[Abstract].
|
| 13.
|
Chen, D. X.,
J. C. McMichael,
K. R. VanDerMeid,
D. Hahn,
T. Mininni,
J. Cowell, and J. Eldridge.
1996.
Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization.
Infect. Immun.
64:1900-1905[Abstract].
|
| 14.
|
Chin, N.,
J. Frey,
C. F. Chang, and Y. F. Chang.
1996.
Identification of a locus involved in the utilization of iron by Actinobacillus pleuropneumoniae.
FEMS Microbiology Lett.
143:1-6[Medline].
|
| 15.
|
Cornelissen, C. N.,
G. D. Biswas,
J. Tsai,
D. K. Paruchuri,
S. A. Thompson, and P. F. Sparling.
1992.
Gonococcal transferrin-binding protein 1 is required for transferrin utilization and is homologous to TonB-dependent outer membrane receptors.
J. Bacteriol.
174:5788-5797[Abstract/Free Full Text].
|
| 16.
|
Cornelissen, C. N.,
M. Kelley,
M. M. Hobbs,
J. E. Anderson,
J. G. Cannon,
M. S. Cohen, and P. F. Sparling.
1998.
The transferrin receptor expressed by gonococcal strain FA1090 is required for the experimental infection of human male volunteers.
Mol. Microbiol.
27:611-616[Medline].
|
| 17.
|
Danve, B.,
L. Lissolo,
M. Mignon,
P. Dumas,
S. Colombani,
A. B. Schryvers, and M. J. Quentin-Millet.
1993.
Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals.
Vaccine
11:1214-1220[Medline].
|
| 18.
|
Du, R.,
Q. Wang,
Y.-P. Yang,
A. B. Schryvers,
P. Chong,
D. England,
M. H. Klein, and S. M. Loosmore.
1998.
Cloning and expression of the Moraxella catarrhalis lactoferrin receptor genes.
Infect. Immun.
66:3656-3664[Abstract/Free Full Text].
|
| 19.
|
Faden, H.,
J. Hong, and T. Murphy.
1992.
Immune response to outer membrane antigens of Moraxella catarrhalis in children with otitis media.
Infect. Immun.
60:3824-3829[Abstract/Free Full Text].
|
| 20.
|
Fedorova, N. D., and S. K. Highlander.
1997.
Plasmids for heterologous expression in Pasteurella haemolytica.
Gene
186:207-211[Medline].
|
| 21.
|
Ferreirós, C. M.,
L. Ferrón, and M. T. Criado.
1994.
In vivo human immune response to transferrin-binding protein 2 and other iron-regulated proteins of Neisseria meningitidis.
FEMS Immunol. Med. Microbiol.
8:63-68[Medline].
|
| 22.
|
Gonzalez, G. C.,
R.-H. Yu,
P. Rosteck, and A. B. Schryvers.
1995.
Sequence, genetic analysis, and expression of Actinobacillus pleuropneumoniae transferrin receptor genes.
Microbiology
141:2405-2416[Abstract].
|
| 23.
|
Gray-Owen, S. D.,
S. Loosmore, and A. B. Schryvers.
1995.
Identification and characterization of genes encoding the human transferrin binding proteins from Haemophilus influenzae.
Infect. Immun.
63:1201-1210[Abstract].
|
| 24.
|
Gray-Owen, S. D., and A. B. Schryvers.
1996.
Bacterial transferrin and lactoferrin receptors.
Trends Microbiol.
4:185-191[Medline].
|
| 25.
|
Helminen, M. E.,
I. Maciver,
J. L. Latimer,
L. D. Cope,
G. H. McCracken, Jr., and E. J. Hansen.
1993.
A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model.
Infect. Immun.
61:2003-2010[Abstract/Free Full Text].
|
| 26.
|
Holland, J.,
P. R. Langford,
K. J. Towner, and P. Williams.
1992.
Evidence for in vivo expression of transferrin-binding proteins in Haemophilus influenzae type b.
Infect. Immun.
60:2986-2991[Abstract/Free Full Text].
|
| 27.
|
Irwin, S. W.,
N. Averill,
C. Y. Cheng, and A. B. Schryvers.
1993.
Preparation and analysis of isogenic mutants in the transferrin receptor protein genes, tbp1 and tbp2, from Neisseria meningitidis.
Mol. Microbiol.
8:1125-1133[Medline].
|
| 28.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 29.
|
Lewis, L. A.,
K. Rohde,
M. Gipson,
B. Behrens,
E. Gray,
S. I. Toth,
B. A. Roe, and D. W. Dyer.
1998.
Identification and molecular analysis of lbpBA, which encodes the two-component meningococcal lactoferrin receptor.
Infect. Immun.
66:3017-3023[Abstract/Free Full Text].
|
| 30.
|
Loosmore, S. M.,
Y. P. Yang,
D. C. Coleman,
J. M. Shortreed,
D. M. England,
R. E. Harkness,
P. S. C. Chong, and M. H. Klein.
1996.
Cloning and expression of the Haemophilus influenzae transferrin receptor genes.
Mol. Microbiol.
19:575-586[Medline].
|
| 31.
|
Mathers, K. E.,
D. Goldblatt,
C. Aebi,
R. H. Yu,
A. B. Schryvers, and E. J. Hansen.
1997.
Characterisation of an outer membrane protein of Moraxella catarrhalis.
FEMS Immunol. Med. Microbiol.
19:231-236[Medline].
|
| 32.
|
Mazarin, V.,
B. Rokbi, and M. J. Quentin-Millet.
1995.
Diversity of the transferrin binding protein Tbp2 of Neisseria meningitidis.
Gene
158:145-146[Medline].
|
| 33.
|
Murphy, T. F.
1996.
Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response.
Microbiol. Rev.
60:267-279[Abstract/Free Full Text].
|
| 34.
|
Myers, L. E.,
Y.-P. Yang,
R.-P. Du,
Q. Wang,
R. E. Harkness,
A. B. Schryvers,
M. H. Klein, and S. M. Loosmore.
1998.
The transferrin binding protein B of Moraxella catarrhalis elicits bactericidal antibodies and is a potential vaccine antigen.
Infect. Immun.
66:4183-4192[Abstract/Free Full Text].
|
| 35.
|
Pettersson, A.,
T. Prinz,
A. Umar,
J. van der Blezen, and J. Tommassen.
1998.
Molecular characterization of LbpB, the second lactoferrin-binding protein of Neisseria meningitidis.
Mol. Microbiol.
27:599-610[Medline].
|
| 36.
|
Potter, A. A.,
A. B. Schryvers,
J. A. Ogunnariwo,
W. Hutchens,
R. Y. C. Lo, and T. Watts.
1999.
Protective capacity of Pasteurella haemolytica transferrin-binding proteins TbpA and TbpB in cattle.
Microb. Pathog., in press.
|
| 37.
|
Rokbi, B.,
V. Mazarin,
G. Maitre-Wilmotte, and M. J. Quentin-Millet.
1993.
Identification of two major families of transferrin receptors among Neisseria meningitidis strains based on antigenic and genomic features.
FEMS Microbiol. Lett.
110:51-58[Medline].
|
| 38.
|
Rokbi, B.,
M. Mignon,
D. A. Caugant, and M. J. Quentin-Millet.
1997.
Heterogeneity of tbpB, the transferrin-binding protein B gene, among serogroup B from Neisseria meningitidis strains of the ET-5 complex.
Clin. Diagn. Lab. Immunol.
4:522-529[Abstract].
|
| 39.
|
Rokbi, B.,
M. Mignon,
G. Maitre-Wilmotte,
L. Lissolo,
B. Danve,
D. A. Caugant, and M.-J. Quentin-Millet.
1997.
Evaluation of recombinant transferrin binding protein B variants from Neisseria meningitidis for their ability of induce cross reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains.
Infect. Immun.
65:55-63[Abstract].
|
| 40.
|
Rossi-Campos, A.,
C. Anderson,
G.-F. Gerlach,
S. Klashinsky,
A. A. Potter, and P. J. Willson.
1992.
Immunization of pigs against Actinobacillus pleuropneumoniae with two recombinant protein preparations.
Vaccine
10:512-518[Medline].
|
| 41.
|
Schryvers, A. B., and B. C. Lee.
1989.
Comparative analysis of the transferrin and lactoferrin binding proteins in the family Neisseriaceae.
Can. J. Microbiol.
35:409-415[Medline].
|
| 42.
|
Schryvers, A. B., and L. J. Morris.
1988.
Identification and characterization of the transferrin receptor from Neisseria meningitidis.
Mol. Microbiol.
2:281-288[Medline].
|
| 43.
|
Sethi, S.,
S. L. Hill, and T. F. Murphy.
1995.
Serum antibodies to outer membrane proteins (OMPs) of Moraxella (Branhamella) catarrhalis in patients with bronchiectasis: identification of OMP B1 as an important antigen.
Infect. Immun.
63:1516-1520[Abstract].
|
| 44.
|
Yang, Y. P.,
L. E. Myers,
U. McGuinness,
P. Chong,
Y. Kwok,
M. H. Klein, and R. E. Harkness.
1997.
The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bactericidal antibodies.
FEMS Immunol. Med. Microbiol.
17:187-199[Medline].
|
| 45.
|
Yu, R.-H., and A. B. Schryvers.
1993.
The interaction between human transferrin and transferrin binding protein 2 from Moraxella (Branhamella) catarrhalis differs from that of other human pathogens.
Microb. Pathog.
15:443-445.
|
Infection and Immunity, August 1999, p. 3793-3799, Vol. 67, No. 8
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lipski, S. L., Akimana, C., Timpe, J. M., Wooten, R. M., Lafontaine, E. R.
(2007). The Moraxella catarrhalis Autotransporter McaP Is a Conserved Surface Protein That Mediates Adherence to Human Epithelial Cells through Its N-Terminal Passenger Domain. Infect. Immun.
75: 314-324
[Abstract]
[Full Text]
-
Murphy, T. F., Brauer, A. L., Aebi, C., Sethi, S.
(2005). Identification of Surface Antigens of Moraxella catarrhalis as Targets of Human Serum Antibody Responses in Chronic Obstructive Pulmonary Disease. Infect. Immun.
73: 3471-3478
[Abstract]
[Full Text]
-
Holm, M. M., Vanlerberg, S. L., Foley, I. M., Sledjeski, D. D., Lafontaine, E. R.
(2004). The Moraxella catarrhalis Porin-Like Outer Membrane Protein CD Is an Adhesin for Human Lung Cells. Infect. Immun.
72: 1906-1913
[Abstract]
[Full Text]
-
Mollenkvist, A., Nordstrom, T., Hallden, C., Christensen, J. J., Forsgren, A., Riesbeck, K.
(2003). The Moraxella catarrhalis Immunoglobulin D-Binding Protein MID Has Conserved Sequences and Is Regulated by a Mechanism Corresponding to Phase Variation. J. Bacteriol.
185: 2285-2295
[Abstract]
[Full Text]
-
Murphy, T. F., Kirkham, C., Liu, D.-F., Sethi, S.
(2003). Human Immune Response to Outer Membrane Protein CD of Moraxella catarrhalis in Adults with Chronic Obstructive Pulmonary Disease. Infect. Immun.
71: 1288-1294
[Abstract]
[Full Text]
-
Pearson, M. M., Lafontaine, E. R., Wagner, N. J., St. Geme III, J. W., Hansen, E. J.
(2002). A hag Mutant of Moraxella catarrhalis Strain O35E Is Deficient in Hemagglutination, Autoagglutination, and Immunoglobulin D-Binding Activities. Infect. Immun.
70: 4523-4533
[Abstract]
[Full Text]
-
Verduin, C. M., Hol, C., Fleer, A., van Dijk, H., van Belkum, A.
(2002). Moraxella catarrhalis: from Emerging to Established Pathogen. Clin. Microbiol. Rev.
15: 125-144
[Abstract]
[Full Text]
-
Sethi, S., Murphy, T. F.
(2001). Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review. Clin. Microbiol. Rev.
14: 336-363
[Abstract]
[Full Text]